Spruce Biosciences (OTC:SPRBD) Trading Up 40.9% – Here’s What Happened

Spruce Biosciences, Inc. (OTC:SPRBD)’s stock price traded up 40.9% during trading on Thursday . The company traded as high as $12.75 and last traded at $12.40. 75,838 shares were traded during mid-day trading, an increase of 675% from the average session volume of 9,786 shares. The stock had previously closed at $8.80.

Spruce Biosciences Price Performance

The business’s 50-day moving average price is $12.40. The firm has a market cap of $6.97 million, a price-to-earnings ratio of -0.14 and a beta of 2.43.

Spruce Biosciences, Inc is a clinical-stage specialty biopharmaceutical company focused on developing targeted therapies for rare endocrine diseases. The company’s research strategy centers on modulating the hormonal axis to address underlying disease mechanisms rather than treating symptoms alone. By concentrating on orphan indications with high unmet medical need, Spruce aims to deliver novel treatment options for patients who have limited alternatives under current standard-of-care regimens.

Spruce’s lead product candidate is tildacerfont, an oral corticotropin-releasing factor type 1 (CRF1) receptor antagonist in development for adults with classic congenital adrenal hyperplasia (CAH).